# A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients

> **NCT00368706** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 246 (actual)

## Conditions studied

- Urinary Bladder, Overactive

## Interventions

- **DRUG:** solifenacin succinate
- **DRUG:** tolterodine

## Key facts

- **NCT ID:** NCT00368706
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 246 (ACTUAL)
- **Last updated:** 2008-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00368706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00368706, "A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00368706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*